Delving into the Latest Updates on Jiangsu Dekang Biotechnology Co. Ltd. with Synapse

Overview

Tags

Digestive System Disorders

Other Diseases

Mesenchymal stem cell therapy

Disease domain score

A glimpse into the focused therapeutic areas

No Data

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

No Data

Top 5 Drug Type	Count

Mesenchymal stem cell therapy	1

Primary purpose: To clarify the safety and tolerability of DK001 in the treatment of complex anal fistulas in Crohn's disease, and to determine the safety range and recommended dose of clinical medication for subsequent trials; Secondary purpose: To preliminarily observe the effectiveness of DK001 in the treatment of complex anal fistulas in Crohn's disease, and to provide a basis for the design of subsequent confirmatory clinical trials.

Start Date10 Mar 2022

Sponsor / Collaborator

Jiangsu Dekang Biotechnology Co. Ltd.

100 Clinical Results associated with Jiangsu Dekang Biotechnology Co. Ltd.

Login to view more data

0 Patents (Medical) associated with Jiangsu Dekang Biotechnology Co. Ltd.

Login to view more data

100 Deals associated with Jiangsu Dekang Biotechnology Co. Ltd.

Login to view more data

100 Translational Medicine associated with Jiangsu Dekang Biotechnology Co. Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 22 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 2 Clinical

1

Login to view more data